Novel Abeta immunogens: is shorter better?

Area of Science:

• Neuroscience
• Immunology
• Vaccine Development

Background:

• Active and passive amyloid-beta (Abeta) immunotherapy in Alzheimer's disease (AD) mouse models reduces Abeta and improves cognition.
• A previous clinical trial was halted due to meningoencephalitis, possibly caused by the full-length Abeta1-42 immunogen triggering an autoimmune response.

Purpose of the Study:

• To develop novel Abeta peptide immunogens for active immunization to create a safe and effective AD vaccine.
• To target Abeta B cell epitopes (Abeta1-15) while avoiding Abeta-specific T cell epitopes (Abeta16-42).

Main Methods:

• Intranasal immunization of wildtype and amyloid precursor protein transgenic (APP Tg) mice with dendrimeric Abeta1-15 or tandem repeat Abeta1-15 immunogens.
• Characterization of Abeta antibody titers, B cell epitopes, immunoglobulin isotypes, and T cell responses.
• Assessment of Abeta levels, plaque burden, gliosis, and Abeta in plasma in J20 mice after six months of immunization.

Main Results:

• Intranasal immunization generated robust Abeta titers, with antibodies recognizing a B cell epitope within Abeta1-7 and showing predominantly T-helper 2 (Th2) associated immunoglobulin isotypes.
• Splenic T cells reacted to the immunogens but not full-length Abeta.
• Immunization in J20 mice lowered insoluble Abeta42 by 50%, reduced plaque burden and gliosis, and increased plasma Abeta.
• Transcutaneous immunization with Abeta1-15 also induced high Abeta titers.

Conclusions:

• Short Abeta immunogens induce robust Th2 antibody responses capable of clearing cerebral Abeta without eliciting Abeta-specific T cell reactivity.
• This approach indicates potential for a safer AD vaccine.
• The developed immunogens show promise for both prevention and treatment of Alzheimer's disease.